Why the study?
The study aimed to establish the incidence of AF in breast cancer patients, focusing on staging and anti-cancer treatment, and comparing it to other cancers.
Does the type of anti-cancer therapy or breast cancer staging influence the incidence of atrial fibrillation in breast cancer patients?
Does the type of anti-cancer therapy or breast cancer staging influence the incidence of atrial fibrillation in breast cancer patients?
The incidence of atrial fibrillation in breast cancer patients is 2.7%, and its occurrence is not significantly influenced by the type of anti-cancer therapy or cancer staging.
Answers are grounded in this paper and cite their sources.
AF incidence in BC warrants clinical vigilance during therapy; meta-analysis leaves open therapy-specific risks and comparisons to other cancers.
This study aims to establish the incidence of atrial fibrillation (AF) in breast cancer (BC) patients, focusing on staging and anti-cancer treatment. A meta-analysis was conducted to investigate the incidence of AF in BC patients and compare this incidence to other cancers. Furthermore, we evaluated the occurrence of AF as an adverse effect of biological therapies vs. non-biological therapies vs. biological therapies + non-biological therapies in BC. Finally, we compared the incidence of AF in early BC and metastatic BC. Thirty studies were included. Twenty-two studies focused on BC, encompassing 166,271 patients. In the BC group, 2.7% of patients developed AF, while in the “all cancer” group, 5.8% of patients developed AF. In addition, there was no difference between different types of therapies (p = 0.61) and between early and metastatic BC (p = 0.57). The type of anti-cancer therapy and the staging of BC does not influence AF’s occurrence in this neoplastic disease.
No takes yet. Share an insight, caveat, or question.
Mauro et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: